Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilixadencel + Pembrolizumab in Advanced Cancer
NCT03735290Phase 1Terminated
- Sponsor
- Mendus
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ilixadencel in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), gastric adenocarcinoma and 1 more (6 arms), sponsored by Mendus. Primary endpoints: Frequency of adverse events, Severity of adverse events and 4 more. Started Jan 2019; status: terminated.
02
Drugs
ilixadencel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03735290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735290.